News | January 22, 2021
Syngene Q3 revenue up 13% to Rs. 585 Cr
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Strides Pharma Science Limited is pleased to announce that Aditya Puri joins the Strides Group as an Advisor and also will be a Director of its associate Company, Stelis Biopharma.
Subscribe To Our Newsletter & Stay Updated
